Survodutide Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Survodutide dosing — protocols, safety, and where to buy.
Dose Range
600-6000 mcg (0.6-6 mg) weekly research dosing
Frequency
Once weekly subcutaneous
Cycle Length
12-24+ weeks per protocol; trial protocols extend to 76 weeks
Half-Life
~140-150 hours (weekly dosing supported)
Administration Routes
Quick Reconstitution Calculator
Calculate syringe units instantly
Syringe Draw
10.0 units
2500 mcg/ml · 0.100 ml draw
Dosing Protocols
600 mcg subcutaneous once weekly for 4 weeks. Titrate up only after GI tolerance is established.
1500-3000 mcg (1.5-3 mg) once weekly. Slow titration over 8-12 weeks from beginner dose.
4500-6000 mcg (4.5-6 mg) once weekly. Phase 3 trial top-dose. Requires medical oversight given the GI burden at this level.
Commonly Stacked With
Stacking is uncommon and not well-characterized for an investigational compound. If exploring: low-dose BPC-157 for GI tolerability during the titration phase. Avoid combining with Semaglutide or Tirzepatide - overlapping GLP-1 agonism risks severe GI adverse events.
Side Effects & Safety
Contraindications
Personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome. Pregnancy and breastfeeding. Active pancreatitis. Severe gastroparesis or active inflammatory bowel disease.
Additional Notes
Reconstitute lyophilized powder with bacteriostatic water at lowest practical volume to maximize concentration. Refrigerate reconstituted vial. Use within 28 days of mixing.
Frequently Asked Questions
What is the recommended Survodutide dosage?
The typical dose range for Survodutide is 600-6000 mcg (0.6-6 mg) weekly research dosing. It is usually administered Once weekly subcutaneous. Always start with the lowest effective dose.
How often should I take Survodutide?
Once weekly subcutaneous
Does Survodutide need to be cycled?
Yes, typical cycle length is 12-24+ weeks per protocol; trial protocols extend to 76 weeks.
What are Survodutide side effects?
Trial-reported AEs include: nausea (most common, dose-dependent), vomiting, diarrhea, constipation, decreased appetite, injection-site reactions. Less commonly: tachycardia, blood-pressure changes (glucagon arm). Black box class concerns for GLP-1 family: thyroid C-cell tumor signal in rodents, pancreatitis risk.
Where can I buy Survodutide?
Visit our vendor directory to find trusted sources for Survodutide.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
